The DOI matches its Crossref record.
Lung cancer in young patients: analysis of a Surveillance, Epidemiology, and End Results database.
Abstract
PURPOSE: A large community-based cancer registry was analyzed to determine if the clinicopathologic characteristics and/or survival rates of lung cancer patients under 50 years of age at diagnosis differ from those of patients 50 years of age or greater at diagnosis. PATIENTS AND METHODS: Data regarding demographics, stage, histology, initial therapy, and survival were obtained on all patients with primary bronchogenic carcinoma registered in the metropolitan Detroit Surveillance, Epidemiology and End Results (SEER) registry from 1973 to 1992. RESULTS: Of 31,266 patients, 9.0% were under 50 years of age at diagnosis. Females (40.1% v 31.2%; P < .001) and blacks (28.7% v 21.9%, P < .001) were overrepresented in the younger group compared with the older group. Younger patients had a significantly higher incidence of adenocarcinoma and were less likely to present with local-stage disease (18.6% v 25.2%; P < .001). Younger patients were significantly more likely to undergo surgery and/or combined-modality therapy. Relative survival at 5 years was significantly better in the younger group (16.1% v 13.4%; P < .001), mainly because of better survival in patients with local-stage disease (48.7% v 35.4%; P < .001). In a multivariate analysis, advanced-stage, nonsurgical initial therapy, age 50 years or greater at diagnosis, and male gender were independent negative prognostic factors. CONCLUSION: The overrepresentation of females and blacks in the group of younger patients with lung cancer suggests an increased susceptibility to lung carcinogens in these populations. Overall, this study suggests that lung cancer is not a more aggressive disease in younger patients and that all patients with lung cancer should be managed along the same therapeutic guidelines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The International Epidemiology of Lung Cancer: Geographical Distribution and Secular Trends
Youlden, D. R., Cramb, S. M., & Baade, P. D. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31818020eb · Cited by 812
Modulation of K-Ras-Dependent Lung Tumorigenesis by MicroRNA-21
Hatley, M. E., Patrick, D. M., Garcia, M. R., Richardson, J. A., Bassel-Duby, R., van Rooij, E., & Olson, E. N. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.08.013 · Cited by 626
“Lung cancer is also the leading cause of cancer-related deaths in the world, with NSCLC accounting for 80%of all cases (Ramalingam et al., 1998).”
The 2004 World Health Organization classification of lung tumors
Beasley, M. B., Brambilla, E., & Travis, W. D. (2005) · Seminars in Roentgenology · doi:10.1053/j.ro.2005.01.001 · Cited by 564
Markou, A., Tsaroucha, E. G., Kaklamanis, L., Fotinou, M., Georgoulias, V., & Lianidou, E. S. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2007.101741 · Cited by 441
Radzikowska, E., Głaz, P., & Roszkowski, K. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf187 · Cited by 418
Metadata
- Authors
- Ramalingam, S., Pawlish, K., Gadgeel, S., Demers, R., & Kalemkerian, G. P.
- Venue
- Journal of Clinical Oncology
- Published
- 1998-02
- Volume
- 16
- Issue
- 2
- Pages
- 651-657
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2156324563
- Cited by
- 196
- References
- 0
- FWCI
- 7.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lung cancer in young patients: analysis of a Surveillance, Epidemiology, and End Results database. https://app.cochat.ai/papers/10.1200/jco.1998.16.2.651
- The paper
- Ramalingam, S., Pawlish, K., Gadgeel, S., Demers, R., & Kalemkerian, G. P. (1998). Lung cancer in young patients: analysis of a Surveillance, Epidemiology, and End Results database. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1998.16.2.651
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.